Alan Lotvin - 01 Feb 2022 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Role
EVP&President-PharmacyServices
Signature
/s/ Alan M. Lotvin
Issuer symbol
CVS
Transactions as of
01 Feb 2022
Net transactions value
-$90,634
Form type
4
Filing time
02 Feb 2022, 15:20:38 UTC
Previous filing
28 Dec 2021
Next filing
23 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVS Common Stock Options Exercise $2,186,932 +21,386 +35% $102.26 82,727 01 Feb 2022 Direct
transaction CVS Common Stock Sale $2,277,566 -21,386 -26% $106.50 61,341 01 Feb 2022 Direct F1
holding CVS Common Stock 492 01 Feb 2022 By Children's Trusts
holding CVS Common Stock (restricted) 5,827 01 Feb 2022 Direct
holding CVS Stock Unit 29,851 01 Feb 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CVS Stock Option Options Exercise $0 -21,386 -100% $0.000000* 0 01 Feb 2022 Common Stock 21,386 $102.26 Direct F2
holding CVS Stock Option 27,395 01 Feb 2022 Common Stock 27,395 $104.82 Direct F3
holding CVS Stock Option 32,911 01 Feb 2022 Common Stock 32,911 $78.05 Direct F4
holding CVS Stock Option 22,541 01 Feb 2022 Common Stock 22,541 $62.21 Direct F5
holding CVS Stock Option 70,702 01 Feb 2022 Common Stock 70,702 $54.19 Direct F6
holding CVS Stock Option 140,797 01 Feb 2022 Common Stock 140,797 $58.34 Direct F7, F8
holding CVS Stock Option 120,940 01 Feb 2022 Common Stock 120,940 $74.30 Direct F9
holding CVS Phantom Stock Credits 557 01 Feb 2022 Common Stock 557 $1.00 Direct F10, F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 All sales were effected pursuant to a Rule 10b5-1 plan.
F2 Option became exercisable in four equal annual installments, commencing 4/1/2016.
F3 Option became exercisable in four equal annual installments, commencing 4/1/2017.
F4 Option became exercisable in four equal annual installments, commencing 4/3/2018.
F5 Option became exercisable in four equal annual installments, commencing 4/1/2019.
F6 Option became exercisable in four equal annual installments, commencing 4/1/2020.
F7 The number of shares subject to the option were calculated using a 30-day average price.
F8 Option became exercisable in four equal annual installments, commencing 4/1/2021.
F9 Option becomes exercisable in four equal annual installments, commencing 4/1/2022.
F10 Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
F11 Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.